Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2007-07-31
2007-07-31
Salimi, Ali R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S199100, C435S091100, C435S069100
Reexamination Certificate
active
10573330
ABSTRACT:
Synthetic DNA molecules encoding the HPV45 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV45 L1 protein, wherein said polynucleotides have been codon-optimized for high level expression in a yeast cell. The synthetic molecules may be used to produce HPV45 virus-like particles (VLPs), and to produce vaccines and pharmaceutical compositions comprising the HPV45 VLPs. The vaccines of the present invention provide effective immunoprophylaxis against papillomavirus infection through neutralizing antibody and cell-mediated immunity.
REFERENCES:
patent: 2004/0121465 (2004-06-01), Robinson
patent: WO 96/15247 (1996-05-01), None
patent: WO 98/34640 (1998-08-01), None
patent: WO 99/02694 (1999-01-01), None
patent: WO 01/14416 (2001-03-01), None
patent: WO 01/41799 (2001-06-01), None
patent: WO 02/08435 (2002-01-01), None
patent: WO 03/077942 (2003-09-01), None
patent: WO 2004/084831 (2004-10-01), None
Bosch, et al., “Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective”, J. Nat. Cancer Inst., vol. 87, No. 11, Jun. 7, 1995, pp. 796-802.
Breitburd, et al., “Immunization with Viruslike Particles from Cottontail Rabbit Papillomavirus (CRPV) Can Protect Against Experimental CRPV Infection”, J. of Virol., vol. 69, No. 6, Jun. 1995, pp. 3959-3963.
Delius, et al., “Primer-Directed Sequencing of Human Papillomavirus Types”, Curr. Topics in Microbiology. and Immunology, vol. 186, 1994, pp. 13-31.
GenBank Accession No. Q9Y4Y5, 1999.
Kortula, et al., “Evaluation of Foreign Gene Codon Optimization in Yeast: Expression of a Mouse IG Kappa Chain”, Bio/Technology, vol. 9, Dec. 1991, pp. 1386-1389.
Liu, et al., “Polynucleotide viral vaccines: codon optimization and ubiquitin conjugation enhances prophylactic and therapeutic efficacy”, Vaccine, vol. 20, 2002, pp. 862-869.
McMurray, et al., “Biology of human papillomaviruses”, International Journal of Experimental Pathology, vol. 82, 2001, pp. 15-33.
Neeper, et al., “Expression of the major capsid protein of human papillomavirus type 11 inSaccharomyces cerevisae”, Gene, vol. 180, 1996, pp. 1-6.
Schiffman, et al., “Epidemiologic Evidence Showing That Human Papillomavirus Infection Causes Most Cervical Intraepithelial Neoplasia”, Journal of National Cancer Institute, vol. 85, No. 12, Jun. 16, 1993, pp. 958-964.
Schiller, et al., “Developing HPV virus-like particle vaccines to prevent cervical cancer: a progress report”, Journal of Clinical Virology, vol. 19, 2000, pp. 67-74.
Schiller, et al., “Papillomavirus-Like Partcles: Basic and Applied Studies”, Papillomavirus Reviews: Current Research on Papillomavirus, ed. Leeds, UK: Leeds Medical Information, 1996, pp. 101-112.
Sharp, et al., “Synonymous Codon Usage inSaccharomyces cerevisiae”, Yeast, vol. 7, 1991, pp. 657-678.
Suzich, et al., “Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomavirus”, PNAS, vol. 92, Dec. 1995, pp. 11553-11557.
Tobery, et al., “Effect of vaccine delivery system on the induction of HPV 16 L1-specific humoral and cell-mediated immune responses in immunized rhesus macaques”, Vaccine, vol. 21, 2003, pp. 1539-1547.
Zhou, et al., “Papillomavirus Capsid Protein Expression Level Depends on the Match between Codon Usage and tRNA Availability”, J. of Virol., vol. 73, No. 6, Jun. 1999, pp. 4972-4982.
Brownlow Michelle K.
Bryan Janine T.
Jansen Kathrin U.
Schultz Loren D.
Finnegan Alysia A.
Heber Sheldon O.
Merck & Co. , Inc.
Salimi Ali R.
LandOfFree
Optimized expression of HPV 45 L1 in yeast does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Optimized expression of HPV 45 L1 in yeast, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Optimized expression of HPV 45 L1 in yeast will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3805048